Which Diet Supplements Actually Work: Evidence Grades and Clinical Data

The UK supplement market contains hundreds of products marketed for weight loss. A systematic review published in Obesity Reviews (Onakpoya et al., 2011) examined 33 supplements and found that none had sufficient evidence to support efficacy claims, while several had documented safety concerns. Since then, a handful of ingredients have accumulated more robust trial data. Identifying which supplements have genuine clinical evidence — and what that evidence actually shows — requires examining trial methodology, not marketing copy.

The Evidence Problem in Supplement Research

Before reviewing specific supplements, understanding the evidence hierarchy is essential:

What constitutes adequate evidence: Randomised, double-blind, placebo-controlled trials (RCTs) with adequate sample sizes (typically n>100 for weight outcomes), appropriate follow-up duration (≥12 weeks for weight effects), and publication in peer-reviewed journals with outcome pre-registration.

Common evidence limitations: Many positive supplement trials are industry-funded (introducing sponsorship bias), use surrogate endpoints rather than body weight, have high dropout rates, or use open-label designs. A 2019 analysis in JAMA Internal Medicine found that 70% of trials for supplement weight loss claims had methodological limitations that prevented confident efficacy conclusions.

Regulatory claim standard: EFSA authorises health claims for specific ingredients at specific doses when the evidence from systematic review supports the claim. EFSA has a notably high rejection rate for supplement health claims — approximately 80% of submissions are rejected. EFSA-authorised claims therefore represent a relatively high evidence bar.

Grade A Evidence: Prescription Weight Loss Medications

These are not supplements but are frequently searched alongside them and warrant inclusion for context:

Semaglutide (Wegovy, Ozempic): GLP-1 receptor agonist. STEP 1 trial (Wilding et al., NEJM 2021, n=1,961): 14.9% mean body weight loss versus 2.4% placebo at 68 weeks. NICE-approved for BMI ≥30 with comorbidities via specialist services.

Tirzepatide (Mounjaro): Dual GIP/GLP-1 agonist. SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, n=2,539): 20.9% mean body weight loss at 72 weeks versus 3.1% placebo. Largest pharmacological weight loss effect in trial history. NICE-approved via specialist criteria.

Orlistat (Alli/Xenical): Pancreatic lipase inhibitor, blocking ~30% dietary fat absorption. Cochrane review (2004, updated): approximately 2.9 kg additional weight loss versus placebo at 12 months. Available OTC at 60mg dose (Alli) and prescription at 120mg (Xenical).

Grade B Evidence: OTC Supplements with Meaningful Trial Data

Glucomannan (Konjac Fibre)

Mechanism: Viscous soluble fibre expanding in stomach, delaying gastric emptying, reducing postprandial glucose excursion, and increasing satiety signalling.

Evidence: The Cochrane review by Keithley and Swanson (2005) found modest but consistent weight reduction in RCTs. A 2005 Journal of the American College of Nutrition trial (n=176) found 1.3 kg additional weight loss versus placebo over 5 weeks. Effective dose: 3–4g/day before meals.

EFSA status: EFSA has authorised the health claim that glucomannan contributes to maintaining normal blood cholesterol levels (at 4g/day). Weight reduction claims require use as part of an energy-restricted diet at 3g/day in three doses before meals — a very specific authorised condition.

Limitations: Choking risk reported with tablet/capsule forms without sufficient water. Effect size modest (approximately 0.8 kg over placebo across studies). Requires sustained use within calorie restriction.

Caffeine

Mechanism: Adenosine antagonism increasing sympathetic nervous system activity; thermogenesis via increased noradrenaline; mild appetite suppression.

Evidence: A 2019 Critical Reviews in Food Science and Nutrition meta-analysis of 13 RCTs found caffeine supplementation associated with significant reductions in body weight (mean −1.22 kg), BMI, and body fat percentage. Effects strongest in caffeine-naïve individuals and attenuate with tolerance development (typically within 2–4 weeks of regular use).

Effective dose: 200–400mg/day. Most adults have habitual caffeine intake reducing net effect.

Safety: NHS recommends maximum 400mg/day. Higher doses associated with cardiovascular effects, anxiety, and sleep disruption — particularly relevant for pre-existing hypertension or arrhythmia.

Green Tea Extract (EGCG)

Mechanism: Catechin-caffeine synergy inhibiting catechol-O-methyltransferase (COMT), the enzyme degrading noradrenaline — extending thermogenic catecholamine effects.

Evidence: A 2012 Cochrane systematic review (Jurgens et al.) of 14 RCTs found mean weight loss of 0.95 kg over placebo with 12 weeks green tea intervention. Statistically significant but clinically modest.

Safety concern: High-dose EGCG (>800mg/day) associated with hepatotoxicity in case reports. EFSA issued a 2018 safety assessment warning against green tea extracts providing ≥800mg EGCG/day. Most commercial products provide 400–600mg; doses near this upper limit warrant caution, particularly with existing liver conditions.

Protein Supplementation

Mechanism: Highest thermic effect of food (TEF) of macronutrients (~20–30% of protein calories expended in digestion versus ~5–10% carbohydrate, ~0–3% fat). Protein is the most satiating macronutrient via GLP-1, PYY, and CCK secretion. Preserves lean mass during calorie restriction.

Evidence: Not a single-ingredient supplement in the traditional sense, but protein adequacy is the most consistently evidence-supported dietary variable for weight management. A 2015 American Journal of Clinical Nutrition meta-analysis (Weigle et al.) found high-protein diets (>25% of energy from protein) produced 0.6 kg greater weight loss than standard protein diets over 12 weeks. Effect attributed to combination of satiety, thermogenesis, and lean mass retention.

Practical dose: 1.2–2.0g protein/kg body weight/day. Achievable through food alone; supplements (whey, casein, plant protein) are useful when dietary protein targets cannot be met from food.

Grade C Evidence: Modest or Inconsistent Trial Data

Conjugated Linoleic Acid (CLA): Multiple meta-analyses show approximately 0.1 kg/week fat loss versus placebo, but effect sizes are clinically negligible, and a 2012 American Journal of Clinical Nutrition systematic review noted significant heterogeneity between trials. Long-term safety unclear.

5-HTP (5-hydroxytryptophan): Serotonin precursor with some appetite suppression data in small trials. Interaction risk with SSRIs and MAOIs. Insufficient large-scale trial data.

Chromium picolinate: Several small trials show modest reduction in carbohydrate cravings. A 2013 Cochrane review found insufficient evidence to support use for weight loss.

Grade D/No Evidence: Common Ingredients Without Reliable Trial Support

The following ingredients appear frequently in weight loss supplements but lack credible RCT evidence for weight loss in humans at commercially available doses:

Raspberry ketones — no human RCT data; mechanism extrapolated from animal studies and in vitro research
Garcinia cambogia (HCA) — multiple RCTs; 2011 Journal of Obesity meta-analysis found no statistically significant effect versus placebo; hepatotoxicity case reports
Hoodia gordonii — one small unpublished industry trial; no independent replication
African mango (Irvingia gabonensis) — small, industry-funded trials only; insufficient independent data
Detox/cleanse supplements — no clinical evidence for any mechanism; the liver and kidneys perform detoxification; no supplement improves their function in healthy individuals

The Commercial Reality

A 2022 analysis found that OTC weight loss supplements produce approximately 1–3 kg additional weight loss versus placebo over 12 weeks in the best-evidenced trials. This is statistically real but clinically modest — equivalent to 2–4 weeks of dietary calorie restriction. The majority of commercially available supplements have no independent trial evidence at their specific formulations and doses.

Prescription GLP-1 medications produce 15–21% body weight loss over 12–18 months — an order of magnitude greater effect than any OTC supplement category, reflecting the difference between pharmaceutical mechanisms of action and food-grade ingredient effects.

Practical Framework for Evidence-Based Supplement Decisions

Search PubMed or Examine.com for the specific ingredient — not brand name — and filter for systematic reviews and RCTs published in the past 10 years
Check EFSA's health claims register for EU/UK-authorised claims
Verify the dose in the product matches the trial dose — many products contain sub-therapeutic amounts
Check for third-party testing via Informed Sport or Informed Choice databases
Evaluate total cost per effect — the cost per kilogram of weight loss from a modest OTC supplement versus evidence-based dietary changes is rarely favourable

Disclaimer: This article is for educational purposes only and does not constitute medical advice. For personalised guidance on weight management, consult your GP or a registered dietitian. Prescription weight loss medications require medical assessment and should not be obtained without prescriber oversight.